

**Interagency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM)
Independent Scientific Peer Review Panel Meeting**

**Assessing the Allergic Contact Dermatitis Potential of Chemicals and Products:
Validation Status of New Versions and Applications of the Murine Local Lymph
Node Assay (LLNA)**

**Consumer Product Safety Commission Headquarters
Fourth Floor Hearing Room
Bethesda Towers Building 4330 East West Highway
Bethesda, MD**

Tuesday, March 4, 2008 - Thursday, March 6, 2008

TENTATIVE Agenda and Order of Business*

Tuesday, March 4, 2008

8:30 a.m.

Opening Session

Call to Order and Panel Introductions

Dr. Luster, Panel Chair

Welcome

Dr. Wind, ICCVAM Chair

Overview of ICCVAM Test Method

Dr. Stokes, NICEATM Director

Evaluation Process and Charge to the Panel

Conflict of Interest Statements

Dr. Stokes

Overview of Agenda

Dr. Luster

Allergic Contact Dermatitis Current Regulatory Testing

Dr. Matheson, CPSC

Requirements and Hazard Classification Schemes

The Traditional Murine LLNA Procedure

Dr. Matheson

The LLNA Limit Dose Procedure

Staff Presentation: Method Description and Overview

Panel Discussion

Public Comment Session: LLNA Limit Dose Procedure

Action: Panel Conclusions and Recommendations

The Applicability Domain of the LLNA

Staff Presentation: Description and Overview of the draft Addendum

Panel Discussion

Public Comment Session: Applicability Domain of the LLNA

Action: Panel Conclusions and Recommendations

5:30 p.m.

Adjourn for the Day

** Note:*

This is a tentative schedule. The actual agenda may vary and it is possible that the panel may progress to the next topic earlier than scheduled, even if listed for the following day.

Wednesday, March 5, 2008*

8:30 a.m. Call to Order and Introductions Dr. Luster

The LLNA: DA Method

Method Description and Overview Dr. Idehara, Daicel Chemical Industries
Staff Presentation: Overview of Draft Background Review Document
(BRD) and ICCVAM Recommendations
Panel Discussion
Public Comment Session: LLNA: DA Method
Action: Panel Conclusions and Recommendations

The LLNA: BrdU-FC Method

Method Description and Overview Dr. DeGeorge, MB Research Labs
Staff Presentation: Overview of Draft BRD and ICCVAM Recommendations
Panel Discussion
Public Comment Session: BrdU-FC Method
Action: Panel Conclusions and Recommendations

The LLNA: BrdU-ELISA Method

Method Description and Overview Dr. Takeyoshi, CERl - Japan
Staff Presentation: Overview of Draft BRD and ICCVAM Recommendations
Panel Discussion
Public Comment Session: BrdU-ELISA Method
Action: Panel Conclusions and Recommendations

5:30 p.m. Adjourn for the Day

Thursday, March 6, 2008*

8:30 a.m. Call to Order (10 min) Dr. Luster

Draft ICCVAM Performance Standards for LLNA

Staff Presentation of Draft Performance Standards
Panel Discussion
Public Comment Session: Draft ICCVAM Performance Standards for LLNA
Action: Panel Conclusions and Recommendations

The LLNA for Potency Determinations

Staff Presentation: Use of the LLNA for Assessing Potency
Categories for Skin Sensitization
Panel Discussion
Public Comment Session: Use of the LLNA for Potency Determinations
Action: Panel Conclusions and Recommendations

5:30 p.m. Adjourn

** Note: This is a tentative schedule. The actual agenda may vary and it is possible that the panel may progress to the next topic earlier than scheduled, even if listed for the following day.*